Table 1.

Demographic and clinical characteristics of AEDs-induced cross-reactivity.

Number	Sex	Agea	First culprit drug				Second culprit drug
			Culprit drug	Latency to cADRs(days)	Initial dose (mg/day)	Maximum dose (mg/day)	Culprit drug	Latency to cADRs (days)	Initial dose (mg/day)	Maximum dose (mg/day)
CR1	F	53	CBZ	15	300	600	LTG	9	12.5	12.5
CR2	F	23	CBZ	7	300	500	LTG	13	12.5	25
CR3	M	30	CBZ	32	500	500	OXC	7	25	25
CR4	F	43	CBZ	5	200	200	OXC	6	150	300
CR5	F	24	CBZ	9	200	400	OXC	16	150	450
CR6	M	34	CBZ	13	200	600	OXC	18	150	450
CR7	F	29	CBZ	17	200	600	OXC	17	150	450
CR8	M	17	CBZ	6	200	200	TPM	21	50	100
CR9	F	7	LTG	2	25	25	CBZ	14	200	400
CR10	F	39	LTG	9	25	50	CBZ	13	600	600
CR11	M	24	LTG	11	12.5	25	CBZ	15	200	400
CR12	M	29	LTG	15	12.5	25	CBZ	16	200	500
CR13	M	6	LTG	16	12.5	25	CBZ	8	200	200
CR14	F	20	LTG	7	25	25	OXC	5	300	600
CR15	F	16	LTG	7	12.5	25	OXC	7	300	300
CR16	F	27	LTG	9	25	25	LEV	8	500	500
CR17	F	7	LTG	20	3.125	12.5	VPA	10	250	250
CR18	M	18	LTG	9	12.5	25	TPM	50	50	50
CR19	M	20	PHT	12	100	200	LTG	9	25	25
CR20	F	37	PHT	16	100	300	OXC	13	300	600
CR21	M	28	OXC	7	300	300	LTG	7	100	100
CR22	F	33	VPA	21	500	500	LTG	16	25	50
CR23	F	7	PB	13	50	100	CBZ	7	200	300

^aAge at development of cross-sensitivity.

F, female; M, male; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; TPM, topiramate; VPA, sodium valproate.